With a simple blood sample, the detection of an oncological process can be achieved, thanks to the technology of quantification of CTCs.
Through the RT q-PCR method, the expression of specific tumor biomarkers associated with carcinomas is quantified.
All the information regarding the analyzed markers, their expression levels, points of clinical interest and much more in your OncoCell® report.
Markers for the detection of circulating tumor cells (CTCs).
|Epithelial cell adhesion. Molecular marker used for the detection of CTC.|
|Epithelial cadherin (E-CAD) marker gene used for the detection of CTC|
|Cytokeratin 7. Marker for CTC detection.|
|CK-20 (KRT20)||Cytokeratin 20. Marker for CTC detection|
Markers for monitoring cell growth.
|Cell growth factor. Prognostic marker used for breast cancer.|
|EGF receiver. Growth marker present in breast, lung, colorectal cancer among others.|
|VEGF (VEGFA)||Growth factor that stimulates angiogenesis.|
|Progesterone receptor. Hormonal marker|
|Estrogen receptor Hormonal marker|
|Molecular marker in tissue with cells derived from prostate cancer.|
|COX2 (PTGS2)||Cyclooxygenase-2 synthase of prostaglandin, promotes tumor progression, resistance to chemotherapeutic agents.|
Targeted therapy markers
|Cell growth regulator. Associated with ovarian cancer.|
|EGF receiver. Good diagnostic marker for breast, ovarian, lung, prostate, stomach and bowel cancer.|
|Suppression of the immune system. The high tumor expression of PDL1 is associated with greater tumor aggressiveness.|